复杂主动脉瘤全腔内修复的适应与结果:开窗与分支腔内修复的短期和中期结局
该研究回顾性分析了2010至2015年间在欧洲主动脉中心接受全腔内修复的71例复杂腹主动脉瘤或胸腹主动脉瘤患者,其中47例为开窗腔内修复,24例为分支腔内修复。30天死亡率为2.8%,90天死亡率为9.9%,3年总体生存率为77.9%±5.6%。结果表明,大型多中心研究所显示的全腔内治疗复杂主动脉瘤的获益可在具备专门主动脉服务的中心复制。
要点
- 全腔内修复复杂主动脉瘤的30天死亡率为2.8%,90天死亡率为9.9%。
- 3年总体生存率为77.9%±5.6%,近肾/肾旁腹主动脉瘤为90.9%±5.2%,胸腹主动脉瘤为60.7%±10.3%。
- 靶血管血运重建成功率为98.6%,技术成功率为95.7%,3年免于分支不稳定的比例为92.7%±2.5%。
核心结论
- 大型多中心研究显示的全腔内治疗复杂主动脉瘤的获益可在其他具备专门主动脉服务的中心适应和复制。
- 本研究结果有助于指导未来如何转诊或治疗这一复杂患者群体。
研究设计与样本
- 回顾性纳入2010至2015年间在欧洲主动脉中心接受腔内主动脉修复(EVAR)的所有近肾/肾旁腹主动脉瘤或胸腹主动脉瘤患者,包括择期、急症和再手术病例。
- 共71例患者,其中近肾/肾旁腹主动脉瘤40例,胸腹主动脉瘤31例(II型14例、III型4例、IV型13例);47例行开窗腔内修复(FEVAR,包括2例医师改良开窗移植物),24例行分支腔内修复(BEVAR)。
- 分析技术成功率和30天、90天死亡率,并用Kaplan-Meier曲线估计3年生存率;靶血管结局报告为随访期间免于分支不稳定。
主要发现
- 30天死亡率为2.8%(n=2),90天死亡率为9.9%(n=7)。
- 3年总体生存率为77.9%±5.6%,近肾/肾旁腹主动脉瘤为90.9%±5.2%,胸腹主动脉瘤为60.7%±10.3%。
- 移植物部署成功69/71例;205/208根靶血管(98.6%)血运重建成功,其中肠系膜上动脉51/51、腹腔干27/27、肾动脉127/130。
- 技术成功率为95.7%(68/71);5例患者(7.0%)出现9例分支不稳定(BEVAR 5例,FEVAR 4例);7根血管(5根肾动脉和2根肠系膜上动脉)接受再干预(5例狭窄、1例闭塞、1例支架移位)。
- 3年免于分支不稳定的比例总体为92.7%±2.5%,BEVAR为88.6%±6.4%,FEVAR为94.6%。
临床怎么用
- 对于复杂腹主动脉瘤(近肾/肾旁)和胸腹主动脉瘤,全腔内开窗或分支修复可在有专门主动脉服务的中心作为开放手术的替代方案开展。
- 术后需关注分支不稳定和靶血管再干预,尤其是肾动脉和肠系膜上动脉。
局限性
- 原文未报告局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study reports the feasibility of adopting a total endovascular approach for the treatment of complex abdominal aortic aneurysms (AAAs) at a European aortic center and compares the short- and midterm results against those from large and multicenter studies. METHODS: All patients treated endovascular aortic repair (EVAR) for juxta/pararenal AAAs or thoracoabdominal aortic aneurysms (TAAAs), both elective and acute, as well as reoperations, from 2010 to 2015 were included. Treatment was fenestrated (FEVAR) or branched (BEVAR), and outcomes were analyzed for technical success and mortality at 30 and 90 days and by Kaplan-Meier curve estimates at 3 years. Outcomes on target vessels were reported as freedom from branch instability in the follow-up period. Reinterventions, endoleaks and perioperative and postoperative morbidities were analyzed. RESULTS: A total of 71 patients were treated for juxta/pararenal AAA (n = 40) or TAAA (n = 31): 14 type II, 4 type III, and 13 type IV. There were 47 FEVAR (including 2 physician-modified fenestrated grafts) and 24 BEVAR procedures performed. Four TAAAs were ruptured. No open repairs were performed for these pathologies in this period. Mortality was 2.8% (n = 2) at 30 days and 9.9% at 90 days (n = 7). One late rupture occurred in a patient whose treatment was a technical failure. Survival at 3 years was 77.9% ± 5.6% overall, 90.9% ± 5.2% for juxta/pararenal AAAs, and 60.7% ± 10.3% for TAAAs. Graft deployment was successful in 69 of 71 patients. Revascularization was successful in 205 of 208 target vessels (98.6%): 51 of 51 superior mesenteric arteries, 27 of 27 celiac arteries, and 127 of 130 renal arteries. There were 131 fenestrated bridging stent grafts and 74 branched bridging stent grafts. Technical success was 68 of 71 (95.7%). There were nine cases of branch instability (5 BEVARs, 4 FEVARs) in five patients (7.0%). Seven vessels (5 renal arteries and 2 superior mesenteric arteries) underwent reintervention: 5 for stenoses, 1 for occlusion, and 1 for stent migration. Freedom from branch instability at 3 years was 92.7% ± 2.5% overall, 88.6% ± 6.4% for BEVAR, and 94.6% for FEVAR. CONCLUSIONS: The short- and midterm results obtained here indicate that the benefits of a total endovascular treatment for complex aortic aneurysms, as demonstrated by large and multicenter studies, can be adapted and replicated at other centers with a dedicated aortic service. This may help guide future considerations of how to refer or treat this complex patient group.
引用
- Budtz-Lilly J, Wanhainen A, Eriksson J, et al. Adapting to a total endovascular approach for complex aortic aneurysm repair: Outcomes after fenestrated and branched endovascular aortic repair. J Vasc Surg. 2017. PMID: 28647195. doi:10.1016/j.jvs.2017.03.422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。